INTRODUCTION
The skeletal muscle ryanodine receptor (RYR1) gene encodes the sarcoplasmic reticulum junctional face membrane calcium release channel ryanodine receptor (RyR1), which plays a crucial role in excitation-contraction (E -C) coupling (1 -6) . The RyR1 ion channels are large protein complexes composed of four RyR 560 kDa peptides and various associated proteins with a total molecular weight of .2500 kDa. They play a crucial role in skeletal muscle E -C coupling by releasing calcium ions required for muscle contraction from the sarcoplasmic reticulum. Disease phenotypes associated with more than 80 dominant RYR1 mutations identified to date include central core disease (CCD) (OMIM no. 117000) and the malignant hyperthermia susceptibility (MHS) trait (MH; OMIM no. 145600) (reviewed in 7-10). More recently, few # The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org recessive mutations have been reported in association with patients affected by multi-minicore disease (MmD) (OMIM no. 602771) (11 -14) and forms of CCD with unusual or more severe presentations (15) . MHS-related RYR1 mutations are predominantly located in the hydrophilic N-terminal and central portions of the RyR1 protein, whereas CCD-related RYR1 substitutions mainly occur in the hydrophobic pore-forming region of the channel (16 -21) . To date, only few recessive RYR1 mutations have been identified and they appear to be distributed throughout the entire gene (11, 12, 14) (Zhou et al., personal communication).
Investigation on the functional properties of RYR1 mutations is crucial for the understanding of the molecular mechanisms associated with RYR1-related clinical phenotypes. Although it is widely accepted that MH-causing RYR1 mutations increase the sensitivity of the RyR1 to activation by pharmacological reagents such as caffeine or 4-chloro-m-cresol (22 -26) and CCD mutations attenuate channel activity and Ca 2þ conductance (20,21,26 -29) , the molecular mechanisms associated with recessively inherited RYR1-related phenotypes are currently only partially understood (30) .
In the following report, we identified RYR1 mutations in three families with clinical features of a congenital myopathy with multiple cores on muscle biopsy. Functional properties of these RYR1 mutants were distinct from those previously reported in CCD and depended on the substituted residues and their location: (i) the presence of the p.Ala1577Thr þ p.Gly2060Cys substitutions in trans (in family 1) reduced RyR1 expression level, without noticeably affecting the functional properties of the recombinant RyR1 ion channel; (ii) the compound p.Arg109Trp þ p.Met485Val substitutions in cis in family 2 also reduced the endogenous RyR1 expression level in muscle, but in addition affected the ability of recombinant channels expressing both substitutions to conduct Ca 2þ ; (iii) the p.Ser71Tyr and p.Asn2283His substitutions in trans in family 3 affected both channel stability and activity. These results suggest that some RYR1 mutations may not only affect Ca 2þ homeostasis directly, but also impair RyR1 function because they significantly affect the stability of the RyR1 complex. Finally, this report shows that in some patients harbouring RYR1 mutations the disease phenotype is associated with silencing of the 'normal' allele.
RESULTS

Patient phenotype, mutation screening, histological examination and family history
In this study, we examined four patients from three different families displaying a similar clinical phenotype: all patients presented clinical manifestations during the neonatal period showing muscle weakness, hypotonia and feeding difficulties, followed by delayed motor milestones. One of the two siblings in family 2 required prolonged ventilation in the neonatal period; the affected child in family 3 had bilateral hip dysplasia for which he was operated at the age of 3 months; the propositus in family 1 had bilateral talipes for which surgery was performed at the age of 10 months. Marked axial weakness and feeding difficulties with subsequent poor weight gain characterized all affected children, requiring gastostomy intervention in the two siblings of family 2 who also had ophthalmoplegia. All affected children acquired the ability to walk, although late, between 18 and 24 months, and they remain ambulant but only for relatively short distance. They all have difficulties in rising from the floor and climbing stairs; respiratory muscle weakness leading to frequent chest infection was a particularly prominent feature in families 1 and 2 and indicates a more severe phenotype of these families compared with family 3. Figure 1 shows the family tree and genetic characterization of the patients and their family members studied. The three families carried compound heterozygous substitutions in their RYR1. Screening of the entire RYR1 cDNA was performed in order to exclude the presence of other amino acid substitutions.
In family 1, the p.Ala1577Thr substitution was transmitted from the mother and was not found in 100 control chromosomes, whereas the paternally transmitted p.Gly2060Cys substitution was previously reported as a polymorphism (7, 31) . We determined the frequency of the polymorphic p.Gly2060Cys substitution in 50 individuals of the general population and 28 patients affected by core myopathies. Seven controls and four patients carried this variation, indicating a similar distribution in the two populations, further suggesting this to be a polymorphism.
The two siblings in family 2 showed transcription of only one allele in muscle, whereas they clearly carried two alleles at the genomic level. These patients transcribed in muscle the allele containing the two substitutions p.Arg109Trp and p.Met485Val, inherited from the asymptomatic father. However, p.Met485 is not a conserved residue and shows as leucine in all other species, suggesting it probably as a polymorphism.
In family 3, the patient harbours two substitutions, p.Ser71Tyr and p.Asn2283His transmitted each from one asymptomatic parent. The monozygotic twins are apparently asymptomatic but could not be studied genetically.
The presence of the mutations was confirmed by RT -PCR analysis using myotubes derived from satellite cells in family 1 and using myotubes derived from skin fibroblasts transduced with MyoD-encoding adenovirus in families 2 and 3 (discussed subsequently). Figure 1C shows the results obtained after PCR amplification and sequencing. In the proband of family 3, the cDNA from MyoD-transformed myotubes has a genotype identical to that found in the patient's muscle tissue. Interestingly, in family 2, both the paternal and maternal alleles were transcribed in the fibroblasts transduced with MyoD. This clearly differed from the pattern of transcription in the skeletal muscle biopsies, in which only the paternal allele was transcribed (described earlier).
The histopathological features of the biopsies from the three affected families are compatible with those now known to be associated with RYR1 mutations. The muscle biopsy from patient 1 showed mild variation in fibre size, an increase in internal nuclei, some of which were central, and a little endomysial connective tissue ( Fig. 2A) . Oxidative enzyme staining revealed multiple focal areas devoid of stain, as well as some single cores of moderate size, and some peripheral aggregation of stain ( Fig. 2D and G) . Fibre typing was indistinct with NADH-TR staining and most fibres expressed slow myosin.
The biopsy from one affected child in family 2 showed a wide variation in fibre size with atrophy and hypertrophy. Several fibres had internal nuclei, many of which were central (Fig. 2B ). Some fibres also showed red stained rod-like structures with the Gomori trichrome stain. Oxidative enzyme stains showed large areas devoid of stain, and obliquely sectioned fibres suggested that these core areas were focal but often spanned the width of the fibre ( Fig. 2E and H). Fibres with slow myosin were predominant.
The muscle biopsy from the affected child in family 3 showed moderate variation in fibre size and no increase in internal nuclei (Fig. 2C) . Oxidative enzyme stains showed prominent core areas in several fibres, which were often peripheral, as well as unevenness of oxidative enzyme stain and uniform fibre typing (Fig. 2F) . No longitudinally sectioned fibres were present from this biopsy to assess the length of the cores.
Immunoblot analysis of muscle samples
Western blot analysis on total protein extracts revealed low levels of RyR1 in the total protein extract from the muscle from patients of families 1 and 2 harbouring the p.Ala1577Thr þ p.Gly2060Cys (Fig. 3, lane 1 ) and p.Arg 109Trp þ p.Met485Val (Fig. 3, lane 2) substitutions compared with the control. Muscle samples from the p.Ser71Tyr þ p.Asn2283His patient and control showed similar levels of RyR1 (Fig. 3, lanes 3 and 4) ; the intensity of the immunoreactive band corresponding to desmin was similar in all samples tested. The results suggest that the RyR1 mutations in families 1 and 2 affect RyR1 protein expression and/or stability.
MyoD-transduced fibroblasts express proteins characteristic of differentiated skeletal muscle
We also considered the possibility that the amino acid substitutions may compromise RyR1 function by performing cellular Ca 2þ release measurements in myotubes. Because myotubes derived from satellite cells of muscle biopsies are not always available, and in our case were not available from families 2 and 3, in initial experiments we tested whether myotubes obtained by adenovirus-mediated MyoD transduction of control skin fibroblasts could be used to characterize the RyR1 mutants. Figure 4 shows indirect immunofluorescence analyses of untransduced fibroblasts (left panels) or skin fibroblasts from a control, transduced with MyoD and differentiated for 5-7 days (right panels). We found that the differentiated cells express markers of skeletal muscle cells such as desmin and myosin; they also express both the dihydropyridine receptor (DHPR) and the RyR1. No immunoreactivity was present for these skeletal muscle proteins in skin fibroblasts. Figure 5A shows that myotubes derived from MyoD-transduced fibroblasts also express a functional RyR1 ion channel, as stored Ca 2þ could be released via the DHPR, by adding 150 mM KCl (Fig. 5A ) and pharmacologically by 4-chloro-m-cresol (which activates RyR1 independent of DHPR) (Fig. 5B) . Figure 5C compares the sensitivities to pharmacological activation of control myotubes derived from differentiating myoblasts by serum deprivation with those derived from control MyoD-transduced fibroblasts. The peak of the Ca 2þ transients elicited by agonist was determined and used to construct dose-dependence curves. Both kinds of myotubes respond to KCl, 4-chloro-m-cresol and caffeine: the maximal increase in fluorescence and EC 50 for ] i ) of myoD-tranduced myotubes obtained from (i) compound heterozygous affected individuals, (ii) heterozygous parents when available and (iii) control individuals (Fig. 6 ). The resting fluorescence ratio observed in cells from affected patients and healthy parents was not significantly different from that observed in control cells, for all amino acid substitutions, except for cells carrying the p.Ser71Tyr þ p.Asn2283His RYR1 substitution (P , 0.00001) (Fig. 6 ). Of interest, the resting [Ca 2þ ] i of myotubes derived from MyoD-transduced fibroblasts was slightly lower (10 -20 nM) than that observed in myotubes derived from primary muscle cultures.
Next we determined whether a decrease in SR Ca 2þ release was responsible for the weak muscle phenotype of the patients harbouring recessive RYR1 mutations. Table 1 compares the peak Ca 2þ release (R max ) obtained by treating myotubes with KCl and caffeine. None of the substitutions caused a significant decrease in the peak Ca 2þ release when compared with that observed from control cells or cells obtained from unaffected family members. Of interest, cells carrying the p.Ser71Tyr þ p.Asn2283His RYR1 substitution were more sensitive to RyR1 activation and behaved like cells from MHS individuals. Although peak Ca 2þ release (R max ) was not significantly affected (Table 1) , the EC 50 was reduced bỹ 50% (from 20.1 + 0.03 to 10.7 + 0.04 for KCl and 6.1 + 1.2 to 1.9 + 0.1 for caffeine in MyoD myotubes from control and p.Ser71Tyr þ p.Asn2283His, respectively).
Functional properties of mutant RYR1s expressed in HEK293 cells
In order to gain a more comprehensive view of the effects of the mutations on RyR1 channel function, we expressed rabbit RyR1s carrying the recessive mutations in a heterologous (HEK293) cell system that lacks endogenous RyRs. Note that in the cells expressing the recombinant rabbit RyR1 cDNA, the rabbit nomenclature for residues is used. The expression levels and functional properties of the recombinant RyR1 mutants were determined by cellular fluorescence microscopy, immunoblot analysis and [
3 H]ryanodine binding. Single channels were recorded to determine the ion permeation properties of the mutants.
The fluorescence change of Fluo-4 was measured to detect Ca 2þ release in response to 10 mM caffeine or 400 mM 4-chloro-m-cresol in HEK293 cells that expressed wild-type (WT) and mutant RyR1s. Similar time courses and peak amplitudes of Ca 2þ release were observed for cells expressing WT and Ala1578Thr, Ser2060Cys, Leu486Val, Ser71Tyr and Asn2283His RYR1 mutant channels, whereas vectortransfected cells and cells transfected with cDNAs carrying Arg110Trp or Arg110Trp þ Leu486Val substitutions showed We also expressed in HEK293 cells RyR1-Ala1578Thr and RyR1-Ser2060Cys or RyR1-Ser71Tyr and RyR1-Asn2283His mutants in 1:1 ratio to match their simultaneous expression in families 1 and 3. Co-expression of RyR1-Ala1578Thr and RyR1-Ser2060Cys yielded a B max value (Fig. 7A) and Ca 2þ -dependence (Fig. 7B) Figure 8 compares single-channel activities and ion permeation properties of WT ion channels with two mutant channels. Shown are RyR1-Asn2283His which exhibited an apparent increased activity in [ 3 H]ryanodine binding experiments and RyR1-Arg110Trp þ Leu486Val which failed to show a caffeine and 4-chloro-m-cresol response in HEK293 cells. Single-channel measurements were performed using the planar lipid bilayer method. Proteoliposomes containing the purified channels were fused with planar lipid bilayers, and single channels were initially recorded in 250 mM KCl on both sides of the bilayer with K þ as the current carrier. The cis (cytosolic) and trans (SR lumenal) bilayer chambers contained micromolar-activating Ca 2þ (2 mM). To ascertain retention of pharmacological regulation, cytosolic Ca 2þ concentrations were reduced to 0.1 mM. To determine Ca 2þ currents (at 0 mV) as well as Ca 2þ selectivity, WT and mutant channels were recorded in 250 mM symmetrical KCl with 10 mM Ca 2þ in the trans (SR lumenal) bilayer chamber. We found that RyR1-Asn2283His showed an increased singlechannel open probability (P o ) compared with WT at both 2 and 0.1 mM cis Ca 2þ as well as with 10 mM trans Ca 2þ as conducting ion (Fig. 8A and B, Table 2 ). Kinetic analysis showed that the mutation increased P o at 2 mM cytosolic Ca 2þ by raising the mean open time without significantly changing the number of single-channel events or mean close time (legend of Fig. 8 ). Single-channel activities of RyR1-Arg110Trp þ Leu486Val were high, but did not respond to a change in cytosolic Ca 2þ concentration (Fig. 8A , Table 2 ). Moreover, no single-channel currents were measured at 0 mV with 10 mM Ca 2þ in the trans chamber. K þ currents of WT, Arg110Trp þ Leu486Val and Asn2283His RyR1 channels, measured in symmetrical 250 mM KCl, showed a linear voltage-dependence (Fig. 8C) . Single-channel conductances were not different for WT and RyR-Asn2283His but were highly variable for RyR Asn2283His, yielding an averaged reduced K þ conductance of 442 + 77 pS (Table 2 ). In the presence of 10 mM Ca 2þ trans at 0 mV, Asn2283His exhibited a unitary Ca 2þ current essentially identical to that of WT RyR1 (Fig. 8C, Table 2 ). Human
Single-channel currents were reduced at elevated positive and negative potentials, and the reversal potentials (E rev ) for WT RyR1 and RyR-Asn2283His were shifted by þ9.5 and þ12.6 mV, respectively. Applying constant field theory, a permeability ratio of Ca 2þ over K þ (P Ca /P K ) of 7.0 and 10.6 was calculated for WT and Asn2283His RyR1 channels, respectively (Table 2 ). In contrast, addition of 10 mM trans Ca 2þ did not generate a noticeable unitary Ca 2þ current at 0 mV and was without effect on K þ currents or reversal potential of RyR1 Arg110Trp þ Leu486Val (Fig. 8C, Table 2 ). Taken together, the single-channel data indicate that the Asn2283His mutation increases Ca 2þ responsiveness and ion selectivity for Ca 2þ compared with K þ , without altering K þ conductance. In contrast, the homozygous Arg110Trp þ Leu486Val mutations abolished Ca 2þ responsiveness and Ca 2þ permeation, and reduced the K þ conductance, demonstrating that the homozygous expression of the Arg110Trp þ Leu486Val mutations introduces major alterations to the channel pore.
DISCUSSION
In this report, we present data relative to newly identified RyR1 amino acid substitutions found in patients with core myopathies, from three families. Our results show that different mutations are associated with different functional outcomes: (i) the p.Ala1577Thr þ p.Gly2060Cys and p.Arg109Trp þ p.Met485Val mutations lead to a decrease in the amount of RyR1 expressed in skeletal muscle. (ii) Heterozygosity for p.Ser71Tyr þ p.Asn2283His results in an 'unstable' protein that looses activity when isolated from HEK293 cells and conveys an MHS phenotype. The mutation responsible for the increased RyR1 sensitivity is the p.Asn2283His. (iii) The homozygous expression of p.Arg109Trp þ p.Met485Val also affects Ca 2þ transport and [ 3 H]ryanodine binding, leading to Ca 2þ dysregulation. In family 2, both affected children exclusively transcribed in muscle the paternal allele carrying the two substitutions, despite being heterozygous at the genomic DNA level. Thus, in addition to more 'conventional' effects of mutations, in some patients affected by core myopathies, haploinsufficiency or allele silencing must be verified, as the genotype of the genomic DNA may not always reflect the transcribed mRNA (Zhou et al., 2006, submitted for publication).
The presence of cores or areas devoid of oxidative enzyme activity and mitochondria exhibiting variable degrees of myofibrillar disruption, is a non-specific feature occurring in several neuromuscular disorders but appears to be a particular feature associated with mutations in the RYR1 gene (33, 34) . In CCD, the large centrally located cores affecting an appreciable number of sarcomeres are predominantly caused by dominant mutations in the RYR1 gene and cause dysregulation of myoplasmic Ca 2þ homeostasis by affecting the amount of Ca 2þ released after RyR1 activation (7, 9, 10) . In other cases, the presence of multiple small cores, with several focal areas per fibre affecting only a few sarcomeres have been associated with recessive mutations in the RYR1 gene; for one of these (the p.Pro3527Ser substitutions), we were able to show that its presence at the homozygous state also affects the amount of Ca 2þ released after direct pharmacological activation of the RyR1 (30) . Though some clinical features of patients with minicore myopathy may appear to overlap with those observed in patients with CCD, the two conditions can be distinguished, so it is not surprising that the functional effects of the underlying genetic defects are dissimilar. Of the three compound heterozygous mutations we investigated in this study, we found that the p.Ala1577Thr þ p.Gly2060Cys did not affect Ca 2þ homeostasis in any discernable way, i.e. the resting [Ca 2þ ], the pharmacological activation of Ca 2þ release, the RyR1-dependent IL-6 release (data not shown) and the single-channel properties of recombinant channels harbouring these mutations were unaffected. Thus, either these substitutions are unrelated to the core myopathy and search for mutation(s) in other genes must be undertaken or the effect of the two substitutions operates by a distinct mechanism, for example, the mutations may interfere with the stability of the RyR1 macromolecular complex within the skeletal muscle. In line with this hypothesis, we found that the relative amount of RyR1 protein present in the muscle biopsy from the patient was significantly decreased, whereas the overall level of RyR1 transcript in the patient's muscle and the amount of RyR1 protein over-expressed in HEK293 cells transfected with the cDNA carrying these substitutions were not affected. Thus, the concomitant presence of both substitutions leads to a decrease in the stability of the RyR1 complex causing partial depletion of RyR1 Ca 2þ channels in the skeletal muscle tissue of the patients. A similar finding was reported by Monnier et al. (35) in a patient with MmD and ophthalmoplegia carrying a homozygous splicing RYR1 mutation; in their patient, the presence of a cryptic splicing mutation resulted in a 90% decrease in the normal RYR1 transcript in skeletal muscle.
As to family 2, western blot analysis revealed that the p.Arg109Trp þ p.Met485Val substitutions were also accompanied by a reduction in the amount of RyR1 expressed in muscle tissue. Intracellular Ca 2þ measurements on myotubes derived from MyoD-transduced fibroblasts showed little or no functional effects of the mutations at the heterozygous state. However, transcription analysis disclosed a fundamental difference between skeletal muscle and MyoDtransduced myoblasts, as the former tissue was monoallelic, whereas the latter showed biallelic transcription. It is therefore not surprising that the Ca 2þ measurement in the MyoDtransduced myotubes did not reveal alterations in Ca 2þ homeostasis. Importantly, when HEK293 cells carrying 3 H]ryanodine binding to recombinant RyR1. Therefore, in this family, two mechanisms may partake in causing the myopathy: Ca 2þ dysregulation due to the homozygous expression of the pArg109Trp residue in the patient's skeletal muscle and the concomitant instability of the RyR1 carrying both homozygous substitutions leading to a reduction in the levels of RyR1 protein within skeletal muscle. In this context, it should be mentioned that the clinical phenotypes of patients from both families 1 and 2, in whom we found partial depletion of endogenous RyR1 Ca 2þ channels, were more severe compared with the patient from family 3.
As far as the p.Ser71Tyr þ p.Asn2283His substitutions found in family 3 are concerned, our results demonstrate that their presence leads to unstable channels because no [ 3 H]ryanodine binding was observed on microsomes from transfected HEK293 cells even though control levels of RyR1 were detected on western blots from transfected HEK293 cells and in muscle biopsies. Thus, though in family 3 the mutations do not lead to a significant reduction in RyR1 protein content, we can hypothesize that they affect the stability of the RyR1 macromolecular complex. An additional observation emerging from this study is that myotubes carrying the p.Ser71Tyr þ p.Asn2283His substitutions had a significantly higher resting [Ca 2þ ] and a shift in the sensitivity to pharmacological RyR1 activation, typical features of MHS (24, 26, 36) , and our results support that p.Asn2283His substitution is responsible for conveying the MHS phenotype.
This study also explored the possibility of using primary cultures of fibroblast to study the defects of the protein machinery involved in skeletal muscle E-C coupling, when primary muscle cell cultures are not available. This system offers obvious advantages including the ease of obtaining skin patch biopsies even from children, the capacity of fibroblasts to proliferate rapidly in culture and to be induced to differentiate into myotubes after transduction with MyoD. Nevertheless, our study also has identified some limitations associated with the use of such cells as (i) the cell's genotype should be carefully evaluated in order to confirm that it matches that of the patient's muscle, in order to exclude silencing for the mutation(s) under investigation. (ii) Their resting [Ca 2þ ] is slightly, but significantly lower than that found in myotubes derived from primary muscle cultures and their response to 4-chloro-m-cresol does not saturate. The latter observation may be due to the fact that such cells may also express type 3 RyR which may be activated at millimolar concentrations of 4-chloro-m-cresol (37, 38) . As to higher resting [Ca 2þ ] of myotubes derived from primary muscle cell cultures, this probably reflects the pathways which are undertaken during myoblast differentiation: during 'physiological' myogenesis, the expression of Kir2.1 channels on the plasma membrane cause myoblast hyperpolarization, activation of myogenin and MEF-2 transcription factors and the appearance of T-type Ca 2þ channels which increase the myoplasmic Ca 2þ concentration by allowing an influx of Ca 2þ through the plasma membrane (39, 40) . In contrast, transduction with MyoD artificially induces fibroblasts to initiate a myogenic 
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differentiation without the coordinated and stepwise activation of physiological transcription factors.
In conclusion, we have identified novel RYR1 substitutions in patients with core myopathies and demonstrate that the functional impact of the mutations is complex and different from those typically observed in patients with CCD carrying dominant RYR1 mutations. These substitutions lead to a decrease in RyR1 content within the muscle and/or a decrease in the stability of isolated channels; in one case, the mutations at the homozygous state were also accompanied by the inability to transport Ca 2þ . These results indicate the importance of assessing not only the functional properties of mutated RyR1 channels in core myopathy patients, but also, when possible, the transcriptional status and endogenous muscle RyR1 levels in patients.
MATERIALS AND METHODS
Materials
Fura-2/AM was from Calbiochem. Caffeine was from Merck (Darmstadt, Germany), 4-chloro-m-cresol was from Fluka Chemicals (Buchs, Swizerland). Mouse anti-MyoD monoclonal antibody was from BD Biosciences (Belgium), mouse anti-desmin monoclonal antibody was from DAKO (Denmark), mouse anti-slow muscle myosin monoclonal antibody was from Chemicon (CA, USA), goat anti-DHPR polyclonal antibody was from Santa Cruz (USA) and mouse anti-RyR1 monoclonal antibody was from Abcam (Cambridge, UK). The secondary biotinylated anti-mouse Ig antibody, Hybond-ECL nitrocellulose and ECL plus Chemiluminescence kit were from Amersham (Buckinghamshire, UK). Streptavidine conjugated to Alexa Fluor-594 and Hoechst 33342 were from Molecular Probes (Leiden, The Netherlands). RNA isolation system was from Qiagen. The SuperScript TM III first strand synthesis system for RT -PCR, pfx platinum DNA polymerase and NuPAGE Pre-cast gels were from Invitrogen. Tissue culture media and reagents were from Invitrogen. MyoD adenovirus (Ad5.f50.AdApt.Myod) was from Crucell (The Netherlands). Human embryonic kidney (HEK) 293 cells were obtained from ATCC. FuGENE 6 and complete protease inhibitors from Roche Applied Science (Indianapolis, IN, USA). Phospholipids were from Avanti Polar Lipids (Alabaster, AL, USA). All other chemicals were of analytical grade.
Methods
Patients. As SEPN1 mutations have been identified in 50% of classical severe cases with multiple cores, PCR and direct Their healthy father carried the compound heterozygous substitutions at the genomic level; the entire RYR1 cDNA from the skeletal muscle of the healthy mother was sequenced and found to carry no substitutions, even in the promoter region. A muscle MRI showed a pattern of selective involvement similar to that observed in patients with CCD secondary to C-terminal RYR1 mutations (13); however, the degree of muscle wasting was more pronounced, corresponding to a more severe clinical phenotype. Skin fibroblasts were obtained from the affected children and healthy parents. (Fig. AF1 -3 ). Skin fibroblasts were obtained from the proband but neither muscle tissue nor fibroblasts were available from the unaffected healthy parents.
Histological studies. Needle muscle biopsies were taken from the vastus lateralis under local anaesthesia after informed consent and processed for histological, histochemical and ultrastructural studies according to standard procedures (41) .
Skeletal muscle cell lines and myoD-transduced fibroblasts.
Human skeletal muscle cell cultures were established from a portion of the needle biopsy as previously described (24) . Differentiation of myoblasts into myotubes was achieved by changing the medium from standard growth medium to differentiation medium [Dulbecco's modified Eagle' medium (DMEM) plus 4.5 mg/ml glucose, 0.5% BSA, 10 ng/ml EGF, 0.15 mg/ml creatine, 5 ng/ml insulin, 200 mM glutamine, 600 ng/ml penicillin G and streptomycin and 7 mM HEPES, pH 7.4). For families 2 and 3, it was not possible to obtain myotubes from the muscle biopsies but primary skin fibroblast cultures were established from the probands and unaffected parents. Functional studies were performed on fibroblasts transduced with MyoD-encoding adenovirus in order to achieve myogenic conversion. Briefly, cells were plated on cover slips in 35 mM tissue culture dishes at a density of 1 Â 10 6 cells/plate and allowed to grow at 378C, 5% CO 2 in growth medium (DMEM supplemented with 10% fetal bovine serum). After allowing the cells to grow for 24 h, the adherent fibroblasts were infected by the addition of 1.6 Â 10 8 virus particles (vp)/plate in differentiation medium (DMEM supplemented with 2% horse serum). After incubation for 3 h, cells were allowed to differentiate into multinucleated myotubes by culturing in DMEM plus 4.5 mg/ml glucose, 0.5% BSA, 10 ng/ml EGF, 0.15 mg/ml creatine, 5 ng/ml insulin, 200 mM glutamine, 600 ng/ml penicillin G and streptomycin, and 7 mM HEPES, pH 7.4 for 4-7 days. Such cells express desmin and other myofibrillar proteins and fuse into multinucleated myotubes under appropriate culture conditions (42) .
Mutation screening. Total RNA was extracted from frozen skeletal muscle biopsies using the RNAeasy mini kit following manufacturer's instructions. Five micrograms of total RNA were used for each reverse transcription reaction; complementary DNA (cDNA) was synthesized using the SuperScript III first-strand synthesis system kit, in a final volume of 20 ml. The cDNAs were subsequently used for the following ] i , of the myotubes were monitored with the fluorescent Ca 2þ indicator fura-2 at the single cell level by digital imaging microscopy as previously described (26) . Individual cells were stimulated with a 12-way 100 mM diameter quartz micromanifold computer controlled microperfuser (ALA Scientific) as described. On-line (340, 380 nm and ratio) measurements were recorded using a fluorescent Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a 20Â water-immersion FLUAR objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530). The cells were analysed using an Openlab imaging system and the average pixel value for each cell was measured at excitation wavelengths of 340 and 380 nm.
Changes in the [Ca 2þ ] i in response to caffeine and 4-chloro-m-cresol in HEK293 cells expressing WT and mutant rabbit cDNA RyR1s was monitored with the fluorescent Ca 2þ indicator Fluo-4. Briefly, HEK293 cells grown on glass cover slips were washed three times with PBS buffer and loaded with 5 mM Fluo 4-AM for 1 h at 378C in Krebs -Ringer -Henseleit (KRH) buffer (125 mM NaCl, 5 mM KCl, 1.2 mM KH 2 PO 4 , 6 mM glucose, 1.2 mM MgCl 2 , 2 mM CaCl 2 and 25 mM HEPES, pH 7.4). After loading, cells were rinsed with KRH buffer to remove non-hydrolysed fluophore and kept in KRH buffer for 30 min to complete de-esterification. Individual cells in KRH buffer were defined as region of interest, and average fluorescence increase in response to addition of 10 mM caffeine or 400 mM 4-chloro-m-cresol was measured, using the program ImageMaster (Photon Technology International, Lawrenceville, NJ, USA).
Construction of mutant cDNAs. Single and multiple base changes of rabbit RyR1 cDNA were performed by Pfu-turbo polymerase-based chain reaction using mutagenic oligonucleotides and the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) as described previously (43) . Briefly, subfragments of RyR1 cDNA, subcloned into cloning vectors, served as a template for PCR. The ClaI/ AauI (polylinker-1361) fragment was used for Ser71Tyr and Arg110Trp mutations (corresponding to the human residues Ser71Tyr and Arg109Trp, the AauI/NotI (1361 -2514) for Leu486Val (corresponding to the human residues Met485Val), the AatII/PinAI (3470 -5066) for Ala1578Thr (corresponding to the human residues Ala1577Thr) the PinAI/XhoI (5066 -6598) for Ser2060Cys (corresponding to the human residues Gly2060Cys) and the XhoI-BbrPI (6598 -7692) for Asn2283His. The complete mutated fragments amplified by PCR were confirmed by DNA sequencing. The fragments with mutations were cloned back into the original positions by standard cloning techniques. Finally, expression plasmids for full-length RyR1 with the mutations were constructed by ligating three RyR1 fragments [ClaI/ XhoI (polylinker-6598), XhoI/EcoRI (6598 -11767), EcoRI/ XbaI (11767-polylinker)] and pCMV5 (ClaI/XbaI) expression vector. Nucleotide numbering is as described previously (44) .
Expression of WT and mutant ryr1 proteins in hek293 cells. WT RyR1 and mutant cDNAs were transiently expressed in HEK293 cells transfected with FuGENE 6 according to manufacturer's instructions. Cells were maintained at 378C and 5% CO 2 in high glucose DMEM containing 10% fetal bovine serum and plated the day before transfection. For each 10 cm tissue culture dish, 3.5 mg of cDNA was used. Cells were harvested 48 h after transfection. Crude membrane fractions and proteolipoosmes containing the purified RyR1s were prepared in the presence of protease inhibitors as described (43) .
Immunoblot analyses. Skeletal muscle proteins were extracted in sample buffer consisting of 75 mM Tris -HCl, 1% SDS, plus a cocktail of protease inhibitors (antipain, aprotinin and leupeptin). Thirty microgram of proteins were resolved using a NuPAGE Pre-cast gels (3 -8% Tris-acetate, Invitrogen) and then transferred electrophoretically to nitrocellulose membrane. Nitrocellulose membrane was blocked in 10% semi skimmed milk in Tris-buffered saline buffer and then probed with mouse anti-RyR1 monoclonal antibody and mouse antidesmin monoclonal antibody at room temperature for 1 h.
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